Congratulations to TOPGEAR
The TOPGEAR trial in resectable gastric cancer has now completed patient recruitment! This significant milestone coincides with the important announcement that the trial has just been awarded another National Health and Medical Research Council (NHMRC) grant.
TOPGEAR is the largest trial ever conducted by the AGITG. This multidisciplinary study involved the collaborative efforts of radiation oncologists, medical oncologists and surgeons to determine the optimal adjuvant regimen for potentially curable gastric cancer.
“TOPGEAR is trying to answer one of the most important questions in Upper GI oncology worldwide, and that is to determine the best combination of chemotherapy, radiotherapy and surgery to improve cure rates for patients with gastric cancer,” Study Chair Professor Trevor Leong said.
ASCOLT Recruitment Completed
Congratulations to Professor Eva Segelov, Dr Mark Jeffery and the entire ASCOLT colorectal cancer team for reaching the target accrual of 1,587 patients, including of 476 patients from Australia and New Zealand.
“The ANZ recruitment allocation was increased several times during the recruitment period. Despite the uncertainty of the COVID-19 pandemic, the ANZ sites continued to screen and recruit successfully and there was only one month where no participants were randomised,” Professor Segelov and Dr Jeffery said.
Well done to the team and we look forward to sharing their new milestones and achievements during the follow-up period.
A new publication, ‘Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the AGITG’, has just been published in the Clinical Colorectal Cancer journal.
Congratulations to everyone involved in this publication: Dr Matthew Burge, Professor Peter Gibbs, Professor Stephen Ackland, Professor Niall Tebbutt, Professor Tim Price, Dr Katrin Sjoquist, Dr Catherine Dunn and Dr Wei Hong.
“Whilst more intensive chemotherapy regimens are often used, these have not proven to be superior in terms of overall survival. In view of the progress made with targeted agents in various subgroups of patients with colorectal cancer, this review re-examines the current and potential future role of lighter chemotherapy backbones,” says Dr Matthew Burge.
Trials Closing to Enrolment Soon
FORECAST-1, aims to demonstrate the feasibility of utilising tumour organoids established from fresh tumour biopsies of mCRC for high throughput drug testing to guide clinical decision making. Only two patients are left to finalise recruitment.
NABNEC, a randomised phase II trial of patients with grade 3 neuroendocrine carcinomas (NECs) aiming to determine the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide. Patient enrolment closing 31 December 2021.
Spotlight on Colorectal Cancer Trials
This month, we’re spotlighting some of our open colorectal cancer trials looking to boost patient enrolment.
OXTOX – A phase II randomised study on whether Oxaliplatin neurotoxicity can be reduced with ibudilast in people with metastatic colorectal cancer.
DYNAMIC-III – The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer.
ALT-TRACC – evaluating the impact of delivering all active cytotoxic agents during initial systemic therapy, by way of an alternating treatment schedule versus standard of care.
LICPIC – Assessing the effect of peri-operative intravenous Lignocaine and post-operative Lignocaine neurovascular plane infusion on natural killer cell function in laparoscopic colorectal cancer surgery.
DYNAMIC-Rectal – aims to show that a ctDNA-based approach to adjuvant therapy will lead to substantially less patients receiving adjuvant therapy.
SPAR– A randomised phase II trial building on research that indicates that a statin drug, taken for cholesterol, can lead to better patient responses to chemotherapy and radiotherapy in rectal cancer.
RENO – Prospective Study of ‘Watch and Wait’ Strategy in Patients with Rectal Cancer who have Developed a Clinical Complete Response with concurrent Chemo‐radiotherapy.